ArticleClinical and translational gastroenterology2026
Impact of Newly Introduced Population-Based Screening and the COVID-19 Pandemic on Colorectal Cancer Incidence and Characteristics: A Retrospective Cohort Study.
Article in Clinical and translational gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
introductionIn Hungary, population-based colorectal cancer (CRC) screening was introduced shortly before the onset of COVID-19 pandemic. We aimed to assess the combined impact of these 2 factors on the incidence and characteristics of CRC.
methodsThe retrospective cohort study included all patients with newly diagnosed CRC between 2014 and 2023 and divided into prepandemic with screening (2015-2016, 2019), prepandemic without screening (2014, 2017-2018), pandemic (2020-2021), and postpandemic (2022-2023) subgroups. CRC incidence, diagnostic patterns, and tumor stage were compared across subgroups.
resultsCrude CRC incidence in institution's care area was lower during pandemic (102.51 per 100,000) compared with the prepandemic with screening (117.92 per 100,000; P = 0.060) and postpandemic (120.60 per 100,000; P = 0.044) subgroups. Age-standardized incidence differed significantly only between the prepandemic with screening and pandemic subgroups (125.30 vs 105.88 per 100,000; P < 0.001). During pandemic, the proportion of early-stage (on the American Joint Committee on Cancer 0-I) cancers was significantly reduced compared with the prepandemic with screening subgroup (18.74% vs 25.08%; P = 0.048) and the proportion of T1 cancers was also lower compared with the postpandemic subgroup (6.90 vs 12.2%; P = 0.026). During pandemic, both the annual number of colonoscopies (2,706.00) and the mean number of colonoscopies required to detect 1 CRC (15.56) were markedly lower compared with the prepandemic with screening (4,590.67 and 13.97), prepandemic without screening (3,824.33 and 10.67), and postpandemic (4,573.50 and 15.50) subgroups. DISCUSSION: The COVID-19 pandemic was associated with unfavorable changes in CRC epidemiology. Organized screening may have mitigated the negative impact during the pandemic and postpandemic periods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.